Iovance Biotherapeutics, Inc. (IOVA) Profit Margins
Over the twelve months to 2026-06-30, Iovance Biotherapeutics, Inc. (IOVA) had gross margin 48.4%, operating margin -92.7%, net margin -89.1%, free cash flow margin -91.2%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IOVAIovance Biotherapeutics, Inc.Follow IOVA — free
—
Price chart with a free account
- Market cap
- 6.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Gross margin | 13.1% | 43.2% | 34.3% | 48.4% | |
| Operating margin | -38735.0% | -240.9% | -153.1% | -92.7% | |
| Net margin | -37345.4% | -226.8% | -148.4% | -89.1% | |
| FCF margin | -32305.3% | -221.9% | -127.6% | -91.2% |
USD millions · SEC XBRL
Iovance Biotherapeutics, Inc. — questions
- What is Iovance Biotherapeutics, Inc.'s gross margin?
- 48.4% over the twelve months to 2026-06-30.
- What is Iovance Biotherapeutics, Inc.'s operating margin?
- -92.7% over the twelve months to 2026-06-30.
- What is Iovance Biotherapeutics, Inc.'s net profit margin?
- -89.1% over the twelve months to 2026-06-30.
Every figure on this page comes from Iovance Biotherapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.